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be considered when immediate transplantation is required
but an appropriate alternative donor is not available oth-
erwise.194
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In the present retrospective study we analyzed 382 patients
undergoing HSCT between 1995 and 2011. Of these 115 pa-
tients received an HLA-CmmHSCTand 266 received an HLA-
C matched graft. Only patients with malignant disease were
included in the analysis with no signiﬁcant differences be-
tween patients with HLA-C matched or mm donors. Median
age was 42 (<1-68) versus 41 (<1-65) years in the matched
and mm groups respectively. Early/late disease was 119/147
and 51/64, respectively (ns). Reduced intensity conditioning
was given to 100 patients (38%) among HLA-C matched pa-
tients compared to 42 (37%) in the HLA-C mm group. Mye-
loablative conditioning was similar in both groups. Female
donor to male recipient was given to 20 (8%) in the matched
group versus 19 (17%) in the mm group. Bone marrow was
used as stem cell source in 74 (28%) patients in the HLA-C
matched group compared to 45 (39%) in the mm group (ns).
The remaining patients received PBSC in each group. Median
CD34 cell dose (x106/kg) was 7.2 (0.2-56.4) versus 7.1 (0.3-
28.7), respectively. GVHD prophylaxis consisted of CsA +MTX
in 84% versus 85% of the patients in each group. ATG was
given to all patients before HSCT.
In the present material graft failure (GF) occurred in 9
(3.4%) in HLA-C matched group compared to 7 (6.1%) in the
mm group (ns). In multivariate analysis for GF, major AB0
mismatch (p¼0.03), RIC (p¼0.01) and female donor to male
recipient (p¼0.002) were signiﬁcant risk factors. HLA-C mm
was not found to be signiﬁcant (p¼0.71). Neither had HLA-C
mm any impact onmortality. Signiﬁcant factors associated to
mortality in multivariate analysis were: disease stage
(p<0.001), year of HSCT (p¼0.015) and donor age (p<0.001).
For acute GVHD grades II-IV CsA+MTX (p<0.001) and RIC
(p<0.001) decreased the risk whereas the use of PBSC
(p¼0.016) increased the risk. HLA-C matched patients
compared to HLA-C mm showed no statistical difference
regarding TRM, RFS, mortality, acute GVHD grades II-IV and
relapse incidence. We also analyzed MFI for all HLA-C alleles
which showed no signiﬁcant correlation to outcome.
In conclusion, in the present study we ﬁnd no negative
impact of HLA-C mismatch on outcome after HSCT.195
Successful Engraftment and Full Donor Chimerism in
Patients Undergoing Second Allogeneic Stem Cell
Transplantation with Umbilical Cord Blood
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Background: Patients with graft failure or disease relapse
following allogeneic hematopoietic cell transplant (HCT)
have <10% survival with no intervention. Second HCT in this
situation is becoming more common. Advantages of cordblood (UCB) in this setting include prompt availability of
donor cells, no donor risk during cell procurement, and po-
tential of enhancing the graft versus leukemia effect through
use of highly mismatched grafts. We sought to determine the
feasibility of second allogeneic transplant with UCB.
Methods: Twenty-three patients median age 33 yrs (range
4-69 yrs) received a CB transplant (CBT) as a second alloge-
neic HCT at the Fred Hutchinson Cancer Research Center
between 2006e2013. Indication for second allograft were
relapse (n ¼ 19), graft failure (n ¼ 3) and donor derived MDS
(n ¼ 1). Median time between transplants was 505 days
(range, 55-3515). At the time of second HCT, 19 patients were
in CR and 4 patients had persistent disease. For their second
transplant, 10 patients received reduced intensity condi-
tioning (RIC) with ﬂudarabine (Flu) 200mg/m2, cyclophos-
phamide (Cy) 50 mg/kg and 200-400 cGy TBI, 2 patients
received myeloablative (MAC) conditioning with Flu 75mg/
m2, Cy 120mg/kg and 1200-1320cGy TBI (n ¼ 2), and 11
patients received “midi” conditioning with treosulfan 42mg/
kg, Flu 150-200mg/m2 and 200 cGy TBI. All patients received
GVHD prophylaxis with cyclosporine and mycophenolate
mofeteil. Twenty of the 23 patients received a double CBT
with a median TNC of 4.8 x 107 cells/kg and a median CD34+
of 2.2 x 105 cells/kg. Twelve patients received at least one 4/6
graft; 9 patients received at least one 5/6 graft.
Results:Median time to engraftment was 22 days (range day
6-49) among 21 evaluable patients; 2 patients died prior to
engraftment. Median time to platelet engraftment was 55
days (range 23-83). Day +28 CD3+ chimerism was 100%
second transplant donor in 16 of 19 evaluable patients, and
100% ﬁrst donor in 2. One patient was mixed between ﬁrst
(22%) and second donor (78%). Death prior to Day 100 was
seen in 5 patients (infection/organ failure (n ¼ 3), encepha-
lopathy (n ¼ 1), and relapse (n ¼ 1). Acute grade II-IV and III-
IV GVHD was diagnosed in 18 of 21 and 6 of 21 evaluable
patients respectively, and 9 of 16 evaluable patients devel-
oped chronic GVHD (6 mild, 2 moderate, 1 severe). Disease
free survival, treatment related mortality, and relapse at 2
years was 40%, 33%, and 35% respectively. Patients receiving
MAC/midi vs RIC conditioning experienced a 2-year DFS of 46
vs 15% (p ¼ 0.02) and relapse rate of 26 vs 45% (p ¼ 0.20).
Conclusions: Our results demonstrate quite favorable out-
comes in patients undergoing CBTas a second allogeneic HCT,
with all evaluable patients engrafting and full donor chime-
rism achieved in 16 of 19 patients byDay +28. The use of CB as
the stem cell source is particularly attractive in this setting as
it eliminates the need to put a conventional donor at risk.196
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Human leukocyte antigen (HLA)-mismatced/haploidentical
stem cell transplantation (SCT) is a known risk factor for
human herpesvirus 6 (HHV-6) infection. High plasma HHV-6
DNA loads in peripheral blood have been associated with the
development of HHV-6-associated encephalitis. However,
previous results have been obtained in patients who under-
went HLA-matched SCT or combined populations, including
a small number of HLA-mismatched SCTs.
Table 1









Group 1 2 (18%) 6 (55%) 11
Group 2 12 (34%) 25 (71%) 35
Group 3 74 (63%) 114 (97%) 117
Total 88 (54%) 145 (89%) 163
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HHV-6 reactivation following SCT, we weekly examined
plasma HHV-6 DNA loads using real-time quantitative-po-
lymerase chain reaction methods until ﬁve weeks post-SCT
in 11 unrelated umbilical cord blood transplantation (CBT)
and 42 unmanipulated HLA-mismatched/haploidentical
related SCT (haplo-SCT).
CBT recipients were conditioned with cytarabine 12 g/m2,
cyclophosphamide 120 mg/kg, and total body irradiation
(TBI) 12 Gy as a myeloablative regimen and ﬂudarabine 200
mg/m2, cyclophosphamide 50 mg/kg, and TBI 3 Gy for a
reduced-intensity regimen. Prophylaxis for graft-versus-host
disease (GVHD) consisted of cyclosporine A, with myco-
phenolate mofetil (MMF) or a short course of methotrexate
(sMTX).
Haplo-SCT recipients were conditioned with ﬂudarabine
120 mg/m2, cytarabine 8 g/m2, cyclophosphamide 120
mg/kg, and TBI 8e12 Gy for a myeloablative regimen and
ﬂudarabine 180 mg/m2, rabbit ATG 8 mg/kg (Fresenius,
Munich, Germany) or 4 mg/kg (Genzyme, Tokyo, Japan), and
busulfan 8 mg/kg or melphalan for a reduced-intensity
regimen. Bone marrow and peripheral blood stem cells were
infused freshly without T-cell depletion. GVHD prophylaxis
against myeloablative and reduced-intensity haplo-SCT was
performed with tacrolimus, sMTX, MMF, and methylpred-
nisolone 2 mg/kg, and tacrolimus and methylprednisolone 1
mg/kg, respectively.
Compared to all of 11 CBT recipients (100%), plasma HHV-
6 DNA was detected in 3 of 42 haplo-SCT recipients (7.1%)
despite methylprednisolone use for graft-versus-host dis-
ease prophylaxis. As preemptive therapy, 8 CBT and 3 haplo-
SCT recipients were administered foscarnet or ganciclovir at
a median of four days (range, 0 to 9) after detection of HHV-6
DNA, followed by its rapid resolution except for one CBT
recipient who had repeatedly positive results. The remaining
3 CBT recipients were administered foscarnet before detec-
tion of plasma HHV-6 DNA. Despite HHV-6 reactivation, no
patients developed HHV-6-associated encephalitis.
In the present observations both HLA disparity, and the
use of methylprednisolone and antithymocyte globulin
was not necessarily a risk factor for development of HHV-6
reactivation in our haplo-SCT fashion. Furthermore,
preemptive or prophylactic administration of antivirals
potentially prevents HHV-6-associated encephalitis by
suppression of HHV-6 reactivation at an early stage of SCT.197
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Recent research suggests that beyond 8/8 allele level
matching at HLA-A, B, C, DRB1,matching at HLA-DPB1 should
be considered to improve patient survival rates in allogeneic
stem cell transplantation. DPB1 alleles have been separated
into three T-cell epitope (TCE) groups based on reactivity in
functional assays for matching: 1) high 2) intermediate 3)
low immunogenic potential. Non-permissive TCEmismatches at DPB1 are associated with a higher incidence
of transplant related mortality in patients that have a 10/10
matched donor.
We performed a study to identify the likelihood of having a
DPB1 permissive TCE matched donor for patients with 10/10
high resolution matched donor options (HapLogic predic-
tion of 75%) in the Be The Match Registry. 163 patient
searches from US transplant centers that submitted a pre-
liminary search request with DPB1 typing were evaluated for
DPB1 TCE permissive mismatched donors, either identiﬁed
through existing registry typing or by prospectively typing
up to 10 donors per patient.
88 of 163 patient searches had a DPB1 TCE permissive
mismatch present on the initial search results, 11 patient
searches did not have a potential DPB1 matched donor, and
the remaining 64 patient searches had up to 10 donors per
patient selected for DPB1 typing, prioritizing young male
donors. 57 out of 64 patients were able to ﬁnd a DPB1 TCE
permissive match via donor typing resulting in an overall
TCE permissive match rate of 89%. Table 1 shows the
condensed TCE groups of the patients assessed in the study,
with patients being classiﬁed by their highest immunogenic
TCE reactivity (i.e. 1>2>3). On initial donor search results,
patients carrying any DPB1 TCE group 1 allele found a match
18% of the time, 34% for group 2 and 63% for group 3. Typing
donors signiﬁcantly improved the identiﬁcation of a DPB1
permissive mismatched donor for all 3 groups to 55% for TCE
group 1, 71% group 2 and 97% for group 3.
This study selection process focused on patients with more
productive searches and shows that identifying a DPB1 TCE
permissive matched donor in these cases is likely for the
majority of patients. HLA typing donors who are predicted to
be 10/10 matches for HLA-DPB1 may provide a feasible
strategy for optimizing donor selection regardless of patient
TCE group.198
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Loss of heterozygosity (LOH) for certain HLA class I alleles
provides tumor cells with an efﬁcient mechanism to escape
the T cell immune response. Here we report a case of com-
plete class I LOH in a patient suffering from acute myeloid
leukemia, which was associated with an intriguing HLA-
typing procedure. The patient was diagnosed with AML FAB
M1 and further analysis revealed a nucleophosmin1 (NPM1)
mutation and normal male karyotype 46XY.
In February 2013 two independently collected EDTA blood
samples (S1 + S2) arrived at our lab for HLA testing. Primary
HLA class I and II typing was done for S1 with Sanger
